- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03966534
Blood Test Order and Culture Contamination
May 28, 2019 updated by: Shaare Zedek Medical Center
A Randomized Controlled Study of Blood Test Draw Order to Reduce Blood Culture Contamination
A randomized partially controlled study to examine the effect of blood diversion into a heparin lithium tube on the incidence of blood culture contamination.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
970
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Jerusalem, Israel
- Shaare Zedek Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age > 18
- Presence in Emergency Room during extended office hours (0800-2000 on weekdays(
- Clinical requirement for Blood culture and biochemistry tests from venepuncture
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Control Group
Blood culture obtained as first test after venipuncture and prior to biochemistry test
|
|
EXPERIMENTAL: Diversion Group
Biochemistry test obtained as first test after venepuncture and prior to blood culture
|
Diversion of initial blood obtained at venipuncture to biochemistry tube in order to try and reduce incidence of blood culture contamination
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood culture contamination
Time Frame: up to 7 days from obtaining blood culture
|
Growth of bacteria defined as blood culture contaminants (for example coagulase negative staphylococci in one bottle only).
|
up to 7 days from obtaining blood culture
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient length of stay
Time Frame: up to 3 months from arrival
|
Length of stay from arrival at Emergency room until discharge in hours
|
up to 3 months from arrival
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 1, 2018
Primary Completion (ACTUAL)
February 28, 2019
Study Completion (ACTUAL)
February 28, 2019
Study Registration Dates
First Submitted
May 21, 2019
First Submitted That Met QC Criteria
May 28, 2019
First Posted (ACTUAL)
May 29, 2019
Study Record Updates
Last Update Posted (ACTUAL)
May 29, 2019
Last Update Submitted That Met QC Criteria
May 28, 2019
Last Verified
September 1, 2018
More Information
Terms related to this study
Other Study ID Numbers
- 0177-18-SZMC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Culture Contamination
-
Dr. Behcet Uz Children's HospitalNot yet recruitingBlood Culture Contamination
-
Shaare Zedek Medical Center3M; Magnolia Medical Technologies, Inc.UnknownPreventing Blood Culture Contamination
-
Central Hospital, Nancy, FranceCompletedBacteremia | Contamination | Blood Culture ContaminationFrance
-
Children's Hospital of PhiladelphiaNational Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationAntibiotic Stewardship | Implementation Science | Blood Culture RatesUnited States
-
Dr Riccardo PaceCompletedBlood Contamination of Root Canal During Endodontic TherapyItaly
-
Dr Riccardo PaceCompletedBlood Contamination of Root Canal During Endodontic Therapy
-
University of Maryland, BaltimoreCompletedBacterial Contamination
-
Travis CallahanCompletedUrine ContaminationUnited States
-
University of Sao PauloAstraZenecaUnknownDrug ContaminationBrazil
-
Ibn Sina HospitalBanoon IVF CenterCompleted
Clinical Trials on Blood diversion
-
University of Southern CaliforniaCompleted
-
Ethicon Endo-SurgeryCompleted
-
St Vincent's University Hospital, IrelandRecruitingQuality of Life | Patient Participation | Patient SatisfactionIreland
-
Assiut UniversityRecruiting
-
Faculty Of Medicine And Pharmacy, CasablancaCompleted
-
University of British ColumbiaCompleted
-
Mayo ClinicCompleted
-
University of MiamiRecruitingBladder CancerUnited States
-
Medical University of South CarolinaTerminatedIntracranial AneurysmUnited States
-
National Liver Institute, EgyptUnknownProgressive Familial Intrahepatic CholestasisEgypt